SCHEMBL4130773

SCHEMBL4130773

Cc1ccc(F)cc1-n1nc(CN(C)C(=O)O)cc1S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP2D6 P10635 1/20 0.33
GPBAR1 Q8TDU6 2/20 0.33
KCNQ3 O43525 2/20 0.33
KCNQ2 O43526 2/20 0.33
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.32
KCNE1 P15382 1/20 0.32
KCNQ1 P51787 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
HPGD P15428 1/20 0.31
NAMPT P43490 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3812566 0.92 ALDH1A1 (0.38) ALDH1A1KMT2AMEN1THRBTDP1
SCHEMBL3697696 0.92 ALDH1A1 (0.38) ALDH1A1KMT2AMEN1THRBTDP1
SCHEMBL4125570 0.91 NAMPT (0.34) KMT2AGPBAR1NAMPTHTR2AHTR2C
SCHEMBL4130737 0.90 ALDH1A1 (0.38) ALDH1A1KMT2AMEN1THRBTDP1
SCHEMBL3703585 0.88 HTR2C (0.41) ALDH1A1KMT2AMEN1THRBCYP2D6
SCHEMBL3703586 0.88 ALDH1A1 (0.33) ALDH1A1KMT2AMEN1THRBTDP1
SCHEMBL4118153 0.87 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1THRBTDP1
SCHEMBL3704890 0.86 P2RX7 (0.34) ALDH1A1KMT2AGPBAR1KDM4ESMN1; SMN2
SCHEMBL4131514 0.86 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1TDP1L3MBTL1
SCHEMBL3699498 0.86 ALDH1A1 (0.37) ALDH1A1KMT2AMEN1THRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 ALDH1A1 1497/4885KMT2A 4776/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.